Viñuela, FélixBarro, Angeles2023-02-092023-02-092021http://hdl.handle.net/10668/17326We evaluated the efficacy and safety of Souvenaid (a multinutrient supplement) in patients with mild Alzheimer's disease (AD) in real clinical practice and assessed a potential synergistic effect of acetylcholinesterase (AChE) inhibitors. Clinical Dementia Rating (CDR) scale was evaluated after six months follow-up. Patients were divided into 4 groups according to the treatment they received: Souvenaid + AChE inhibitors (n = 23); only Souvenaid (n = 8); only AChE inhibitors (n = 7); no treatment (n = 16). The Souvenaid + AChE inhibitors and Souvenaid alone groups were associated with significantly lower increases in CDR per month than the AChE inhibitors or no treatment ones. The efficacy of Souvenaid + AChE inhibitors tended to be higher than Souvenaid alone.enAlzheimer’s diseaseFortasyn Connectcognitive dysfunctionobservational studypragmatic clinical trialsAgedAged, 80 and overAlzheimer DiseaseCholinesterase InhibitorsDietary SupplementsFemaleHumansMaleMental Status and Dementia TestsNootropic AgentsProspective Studiesresearch article33682712open access10.3233/JAD-2013571875-8908PMC8150480https://content.iospress.com:443/download/journal-of-alzheimers-disease/jad201357?id=journal-of-alzheimers-disease%2Fjad201357https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150480/pdf